These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 30089097)

  • 1. Pharmacotherapy of ulcerative colitis - current status and emerging trends.
    Ahmad H; Kumar VL
    J Basic Clin Physiol Pharmacol; 2018 Nov; 29(6):581-592. PubMed ID: 30089097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.
    Christensen B; Gibson PR; Micic D; Colman RJ; Goeppinger SR; Kassim O; Yarur A; Weber CR; Cohen RD; Rubin DT
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):486-493. PubMed ID: 29751166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis.
    Pellet G; Stefanescu C; Carbonnel F; Peyrin-Biroulet L; Roblin X; Allimant C; Nachury M; Nancey S; Filippi J; Altwegg R; Brixi H; Fotsing G; de Rosamel L; Shili S; Laharie D;
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):494-501. PubMed ID: 30213584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Golimumab for moderately to severely active ulcerative colitis.
    Kedia S; Ahuja V; Makharia GK
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing pharmacologic management of inflammatory bowel disease.
    Chang S; Hanauer S
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):595-607. PubMed ID: 28475384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ulcerative colitis: prevention of relapse.
    Naganuma M; Sakuraba A; Hibi T
    Expert Rev Gastroenterol Hepatol; 2013 May; 7(4):341-51. PubMed ID: 23639092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety of approved biologics for ulcerative colitis.
    D'Amico F; Parigi TL; Bonovas S; Peyrin-Biroulet L; Danese S
    Expert Opin Drug Saf; 2020 Jul; 19(7):807-816. PubMed ID: 32441228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety of biological pharmacotherapy for the treatment of ulcerative colitis.
    Fiorino G; Bonovas S; Cicerone C; Allocca M; Furfaro F; Correale C; Danese S
    Expert Opin Drug Saf; 2017 Apr; 16(4):437-443. PubMed ID: 28279079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal Healing in Ulcerative Colitis: A Comprehensive Review.
    Boal Carvalho P; Cotter J
    Drugs; 2017 Feb; 77(2):159-173. PubMed ID: 28078646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic Therapies in Ulcerative Colitis: Primi Inter Pares?
    Allocca M; Fiorino G; Gilardi D; Preatoni P; Papa A; Peyrin-Biroulet L; Danese S
    Curr Drug Targets; 2018; 19(7):748-756. PubMed ID: 27231106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on the Use of Biologic Therapy in Ulcerative Colitis.
    Aggarwal A; Sabol T; Vaziri H
    Curr Treat Options Gastroenterol; 2017 Mar; 15(1):155-167. PubMed ID: 28120279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How important is onset of action in ulcerative colitis therapy?
    Masson S; Nylander D; Mansfield JC
    Drugs; 2005; 65(15):2069-83. PubMed ID: 16225364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the management of ulcerative colitis.
    Taba Taba Vakili S; Taher M; Ebrahimi Daryani N
    Acta Med Iran; 2012; 50(6):363-72. PubMed ID: 22837114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis.
    Vickers AD; Ainsworth C; Mody R; Bergman A; Ling CS; Medjedovic J; Smyth M
    PLoS One; 2016; 11(10):e0165435. PubMed ID: 27776175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The biologics of ulcerative colitis.
    Macaluso FS; Renna S; Orlando A; Cottone M
    Expert Opin Biol Ther; 2017 Feb; 17(2):175-184. PubMed ID: 27960557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs.
    Dignass A; Waller J; Cappelleri JC; Modesto I; Kisser A; Dietz L; DiBonaventura M; Wood R; May M; Libutzki B; Bargo D
    J Med Econ; 2020 Apr; 23(4):415-427. PubMed ID: 31858853
    [No Abstract]   [Full Text] [Related]  

  • 17. Maintenance therapy options for ulcerative colitis.
    Chaparro M; Gisbert JP
    Expert Opin Pharmacother; 2016 Jul; 17(10):1339-49. PubMed ID: 27240112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel oral-targeted therapies for mucosal healing in ulcerative colitis.
    Antonelli E; Villanacci V; Bassotti G
    World J Gastroenterol; 2018 Dec; 24(47):5322-5330. PubMed ID: 30598577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review.
    Wu B; Tong J; Ran Z
    Inflamm Bowel Dis; 2020 Jan; 26(1):24-32. PubMed ID: 30980713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.